Empowering precision medicine in rural India by establishment of a molecular genetics laboratory in Bihar: A prospective observational study

ABSTRACT Background: In the era of precision oncology, molecular profiling and targeted therapies are integral to cancer management. However, accessibility remains a challenge in rural India. Objectives: The primary objective was to showcase the lab’s milestones using in-house next-generation sequencing (NGS)/qualitative real-time polymerase chain reaction (qRT-PCR) diagnostic data from patients with cancer. The secondary objective was to highlight the benefits of integrating NGS with precision medicine in rural India despite resource challenges. Materials and Methods: This prospective observational study was conducted at Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur, Bihar, between November 2022 and December 2023. A 72-gene panel was validated as per National Accreditation Board for Testing and Calibration Laboratories (ISO15189/CAP/AMP/NABL) recommendations and implemented in routine clinical testing across multiple cancers. qRT-PCR was also established for detecting actionable mutations in epidermal growth factor receptor ( EGFR exons 18-21) for lung cancer, NRAS/KRAS/HRAS/BRAF genes, and dihydropyrimidine dehydrogenase ( DPYD ) polymorphisms ( DPYD*2A/*13/D949V/IVS10 ) for recommended cases. Results: In one year (November 2022 to December 2023), we performed 146 tests on Indian patients with cancer: 71% ( n = 103) with NGS and the remainder with qRT-PCR. Among NGS cases, 71% ( n = 73) involved lung cancer, while the rest covered various cancer types. Alterations in well-known driver genes were identified across the cancer types, and their frequencies were matching with the incidence reported in Indian literature. Conclusion: Operating high-end technology in a peripheral center grapple with unique challenges, often demanding resourcefulness and innovation. Nevertheless, our laboratory has made significant strides with every test performed in implementing precision medicine in a seemingly remote setting in rural India.

Authors

Institutions

Publication Details

Journal
Cancer Research Statistics and Treatment
Published
2024-10-01
DOI
https://doi.org/10.4103/crst.crst_42_24
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Empowering precision medicine in rural India by establishment of a molecular genetics laboratory in Bihar: A prospective observational study

Sujay Ray, Ravi Kant Singh, L. Radhakrishnan, H. Bharadwaj et al.
Cancer Research Statistics and Treatment
Cancer Genomics and Diagnostics
article

Empowering precision medicine in rural India by establishment of a molecular genetics laboratory in Bihar: A prospective observational study

Sujay Ray, Ravi Kant Singh, L. Radhakrishnan, H. Bharadwaj, Hitesh Goswami, Kaushal Kishore, B. Indira Priyadharshini, Vidya Veldore, Anuradha Choughule, Peddagangannagari Sreekanthreddy, Asoor Santhanam SARAVANAKUMAR, Kshitij D. Rishi, Vyomesh Javle, Pooja Gowda, Amit Dutt, Kumar Prabhash, Prabir Kumar Saha, Sanjay Kumar Singh, Moitri Basu
article en

Abstract

ABSTRACT Background: In the era of precision oncology, molecular profiling and targeted therapies are integral to cancer management. However, accessibility remains a challenge in rural India. Objectives: The primary objective was to showcase the lab’s milestones using in-house next-generation sequencing (NGS)/qualitative real-time polymerase chain reaction (qRT-PCR) diagnostic data from patients with cancer. The secondary objective was to highlight the benefits of integrating NGS with precision medicine in rural India despite resource challenges. Materials and Methods: This prospective observational study was conducted at Homi Bhabha Cancer Hospital and Research Center, Muzaffarpur, Bihar, between November 2022 and December 2023. A 72-gene panel was validated as per National Accreditation Board for Testing and Calibration Laboratories (ISO15189/CAP/AMP/NABL) recommendations and implemented in routine clinical testing across multiple cancers. qRT-PCR was also established for detecting actionable mutations in epidermal growth factor receptor ( EGFR exons 18-21) for lung cancer, NRAS/KRAS/HRAS/BRAF genes, and dihydropyrimidine dehydrogenase ( DPYD ) polymorphisms ( DPYD*2A/*13/D949V/IVS10 ) for recommended cases. Results: In one year (November 2022 to December 2023), we performed 146 tests on Indian patients with cancer: 71% ( n = 103) with NGS and the remainder with qRT-PCR. Among NGS cases, 71% ( n = 73) involved lung cancer, while the rest covered various cancer types. Alterations in well-known driver genes were identified across the cancer types, and their frequencies were matching with the incidence reported in Indian literature. Conclusion: Operating high-end technology in a peripheral center grapple with unique challenges, often demanding resourcefulness and innovation. Nevertheless, our laboratory has made significant strides with every test performed in implementing precision medicine in a seemingly remote setting in rural India.

Cancer Research Statistics and TreatmentVol. 7(4)
Homi Bhabha National Institute (IN), Tata Memorial Hospital (IN), Advanced Centre for Treatment, Research and Education in Cancer (IN)
Industry, innovation and infrastructure
Openalex Percentile: Top 66%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.